{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:14:41Z","timestamp":1773850481329,"version":"3.50.1"},"reference-count":33,"publisher":"Vilnius University Press","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AML"],"abstract":"<jats:p>Background:\u00a0Pharmacological treatment is one of the most effective ways to help psychiatric patients with depressive disorders. However, prescription of antidepressants to children and adolescents creates controversial thoughts due to possible negative effects on the cardiovascular system. Despite being beneficial in controlling serious illnesses, there is less research done on the side effects of antidepressants which would require periodical checkups and cooperation among medical specialists. This literature review was completed to evaluate effects of antidepressants on the cardiovascular system and the necessity of regular assessment while treating children and adolescents.Aim:\u00a0To review the cardiovascular effects of antidepressants prescribed to children and adolescents; to discuss the need for regular patient checkups with a multidisciplinary team: pediatricians, family doctors, cardiologists and children-adolescent psychiatrists.Methodology:\u00a0Literature sources were selected from the\u00a0Pubmed,\u00a0Google Scholar,\u00a0Clinical Key, and\u00a0Research Gate\u00a0databases by following dates from 2013 to 2024 while using the following keywords and their combinations: antidepressant, cardiovascular, side effects, cardiovascular risk, children and adolescents, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), psychotropic medication, antidepressants in pediatrics, atypical antidepressants, benzodiazepines, lipid metabolism.Results:\u00a0Antidepressants, including SSRIs, SNRIs, TCAs, atypical antidepressants and benzodiazepines, are associated with significant cardiovascular risks in children and adolescents. SSRIs, like citalopram and escitalopram, can disturb the heart rhythm by prolonging the QT interval, or increasing the risk of serious arrhythmias. SNRIs have been linked to an elevated blood pressure and heart rate. TCAs are known for their proarrhythmic effects, particularly in overdose situations, posing a high risk of sudden cardiac events. Atypical antidepressants like bupropion can cause cardiovascular disturbances, especially when overdosed. Additionally, less commonly prescribed benzodiazepines contribute to cardiovascular risks when combined with SSRIs during pregnancy, due to increasing the likelihood of congenital heart defects. These risks underscore the importance of careful monitoring, dosage management and thorough cardiovascular assessment when prescribing these medications to children, adolescents, and pregnant women. A team consisting of professional specialists \u2013 children-adolescent psychiatrists, cardiologists, pediatricians and family doctors \u2013 should detect long-term effects of pharmacotherapy by checking up the young patients regularly.Conclusions:\u00a0The use of antidepressants in children and adolescents, though crucial for managing severe psychiatric disorders, raises significant cardiovascular safety concerns. SSRIs, SNRIs, TCAs, atypical antidepressants, and benzodiazepines have varying cardiovascular risks, especially in vulnerable youth populations and during the prenatal period. Given these risks, careful prescribing, close monitoring, creating guidelines and collaboration among healthcare providers are essential to ensure safe and effective treatment. Additionally, more research is needed to fully understand the long-term cardiovascular impacts of these medications in the pediatric population.<\/jats:p>","DOI":"10.15388\/amed.2025.32.1.15","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:15:14Z","timestamp":1744762514000},"page":"52-63","source":"Crossref","is-referenced-by-count":1,"title":["Antidepressant Prescription to Children\/Adolescents and Its Effects on the\u00a0Cardiovascular System, Comprising the Actual Questions of Periodicity of the\u00a0Checkups, Cooperation among Pediatricians, Family Doctors, Cardiologists and Children-Adolescent Psychiatrists"],"prefix":"10.15388","volume":"32","author":[{"given":"Reda","family":"Montvilait\u0117","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6097","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Cardy R, Dhaliwal S, Reddy PS. Antidepressant drug treatment in Child and adolescent Psychiatry. Madridge J Intern Emerg Med. 2017;1(1):31-39. doi:10.18689\/mjiem-1000106","DOI":"10.18689\/mjiem-1000106"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(7):581-601. doi:10.1016\/S2215-0366(20)30137-1","DOI":"10.1016\/S2215-0366(20)30137-1"},{"key":"ref2","unstructured":"Yekehtaz H, Farokhnia M, Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent. 2013;8(4):169-176."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Goldstein BI, Korczak DJ. Links Between Child and Adolescent Psychiatric Disorders and Cardiovascular Risk. Can J Cardiol. 2020;36(9):1394-1405. doi:10.1016\/j.cjca.2020.06.023","DOI":"10.1016\/j.cjca.2020.06.023"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Wu T, Zhou K, Hua Y, Zhang W, Li Y. The molecular mechanisms in prenatal drug exposure-induced fetal programmed adult cardiovascular disease. Front Pharmacol. 2023;14:1164487. doi:10.3389\/fphar.2023.1164487","DOI":"10.3389\/fphar.2023.1164487"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214-232. doi:10.1002\/wps.20765","DOI":"10.1002\/wps.20765"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, Cox GR, Merry SN, Meader N. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev. 2021;5(5):CD013674. doi:10.1002\/14651858.CD013674.pub2","DOI":"10.1002\/14651858.CD013674.pub2"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Gray J, Hill-Daniel J. Are SSRIs an effective pharmaceutical treatment for depression in adolescents? Evidence-Based Practice. 2021;24(9):46-47. doi:10.1097\/EBP.0000000000001200","DOI":"10.1097\/EBP.0000000000001200"},{"key":"ref8","unstructured":"Dwyer JB, Bloch MH. Antidepressants for Pediatric Patients. Curr Psychiatr. 2019;18(9):26-42F."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Czaja AS, Valuck RJ, Anderson HD. Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events. Pharmacoepidemiol Drug Saf. 2013;22(6):607-614. doi:10.1002\/pds.3420","DOI":"10.1002\/pds.3420"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Zito JM, Burcu M. Stimulants and Pediatric Cardiovascular Risk. J Child Adolesc Psychopharmacol. 2017;27(6):538-545. doi:10.1089\/cap.2015.0239","DOI":"10.1089\/cap.2015.0239"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Edinoff AN, Akuly HA, Hanna TA, et al. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021;13(3):387-401. doi:10.3390\/neurolint13030038","DOI":"10.3390\/neurolint13030038"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Uchida M, Spencer AE, Biederman J, et al. A Systematic Evaluation of the QTc Interval and Antidepressants in Youth: An Electronic Health Record Study. J Dev Behav Pediatr. 2015;36(6):434-439. doi:10.1097\/DBP.0000000000000188","DOI":"10.1097\/DBP.0000000000000188"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Crookes DM, Demmer RT, Keyes KM, Koenen KC, Suglia SF. Depressive Symptoms, Antidepressant Use, and Hypertension in Young Adulthood. Epidemiology. 2018;29(4):547-555. doi:10.1097\/EDE.0000000000000840","DOI":"10.1097\/EDE.0000000000000840"},{"key":"ref14","unstructured":"Jane Garland E, Kutcher S, Virani A, Elbe D. Update on the Use of SSRIs and SNRIs with Children and Adolescents in Clinical Practice. J Can Acad Child Adolesc Psychiatry. 2016;25(1):4-10."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Gurbanov A, Kandemir H, Gurbanova L, et al. Antidepressant Poisoning Trends in Pediatric Intensive Care: A Comparative Study of New- and Old-Generation Antidepressants. J Clin Psychopharmacol. 2023;43(2):139-144. doi:10.1097\/JCP.0000000000001668","DOI":"10.1097\/JCP.0000000000001668"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev. 2013;2013(6):CD002317. doi:10.1002\/14651858.CD002317.pub2","DOI":"10.1002\/14651858.CD002317.pub2"},{"key":"ref17","unstructured":"Carlton KJ. Tricyclic and SSRI Usage Influences the Association Between BMI and Health Risk Factors. Master's thesis. York University; 2014."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Qin B, Zhang Y, Zhou X, et al. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability. Clin Ther. 2014;36(7):1087-1095.e4. doi:10.1016\/j.clinthera.2014.06.001","DOI":"10.1016\/j.clinthera.2014.06.001"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Hartford E, Thomas A, Keilman A, et al. Pediatric Toxidrome Simulation Curriculum: Bupropion Overdose. MedEdPORTAL. 2019;15:10846. doi:10.15766\/mep_2374-8265.10846","DOI":"10.15766\/mep_2374-8265.10846"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Tanidir C, Tanidir IC, Tuzcu V. Treatment of depression in an adolescent with cardiomyopathy and arrhythmia. Cardiol Young. 2015;25(7):1418-1420. doi:10.1017\/S1047951114002303","DOI":"10.1017\/S1047951114002303"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Uchida M, Spencer AE, Kenworthy T, et al. A Pilot Study: Cardiac Parameters in Children Receiving New-Generation Antidepressants. J Clin Psychopharmacol. 2017;37(3):359-362. doi:10.1097\/JCP.0000000000000683","DOI":"10.1097\/JCP.0000000000000683"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kuang H, Johnson JA, Mulqueen JM, Bloch MH. The efficacy of benzodiazepines as acute anxiolytics in children: A meta-analysis. Depress Anxiety. 2017;34(10):888-896. doi:10.1002\/da.22643","DOI":"10.1002\/da.22643"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Vasakova J, Duskova J, Lunackova J, et al. Midazolam and its effect on vital signs and behavior in children under conscious sedation in dentistry. Physiol Res. 2020;69(Suppl 2):S305-S314. doi:10.33549\/physiolres.934511","DOI":"10.33549\/physiolres.934511"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Soto-Insuga V, Gonz\u00e1lez-Alguacil E, Garc\u00eda-Pe\u00f1as JJ. Estado epil\u00e9ptico pedi\u00e1trico [Paediatric status epilepticus]. Rev Neurol. 2022;75(8):225-238. doi:10.33588\/rn.7508.2022196","DOI":"10.33588\/rn.7508.2022196"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Elmowafi H, Kindblom JM, Halldner L, Gyllenberg D, Naumburg E. Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006-2018): A nationwide register-based study. Br J Clin Pharmacol. 2024;1-12. doi:10.1111\/bcp.16321","DOI":"10.1111\/bcp.16321"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"McIntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med. 2008;162(10):929-935. doi:10.1001\/archpedi.162.10.929","DOI":"10.1001\/archpedi.162.10.929"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Liu Z, Sun L, Sun F, et al. The abnormalities of lipid metabolism in children and adolescents with major depressive disorder and relationship with suicidal ideation and attempted suicide. Heliyon. 2024;10(9):e30344. doi:10.1016\/j.heliyon.2024.e30344","DOI":"10.1016\/j.heliyon.2024.e30344"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Romba C, Perez-Reisler M. Management of Adverse Effects of Psychotropic Medications. Pediatr Ann. 2020;49(10):e431-e435. doi:10.3928\/19382359-20200922-03","DOI":"10.3928\/19382359-20200922-03"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Bozdag D, van Voorthuizen J, Korpel N, Lentz S, Gurer-Orhan H, Kamstra JH. Dysregulation of adipogenesis and disrupted lipid metabolism by the antidepressants citalopram and sertraline. Toxicol Appl Pharmacol. 2024;486:116937. doi:10.1016\/j.taap.2024.116937","DOI":"10.1016\/j.taap.2024.116937"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Hengartner MP. Editorial: Antidepressant Prescriptions in Children and Adolescents. Front Psychiatry. 2020;11:600283. doi:10.3389\/fpsyt.2020.600283","DOI":"10.3389\/fpsyt.2020.600283"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Stutzman DL. Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing. Ment Health Clin. 2021;11(6):320-333. doi:10.9740\/mhc.2021.11.320","DOI":"10.9740\/mhc.2021.11.320"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Jack RH, Joseph RM, Coupland C, Butler D, Hollis C, Morriss R, Knaggs RD, Cipriani A, Cortese S, Hippisley-Cox J. Secondary care specialist visits made by children and young people prescribed antidepressants in primary care: a descriptive study using the QResearch database. BMC Med. 2020;18(1):93. doi:10.1186\/s12916-020-01560-7","DOI":"10.1186\/s12916-020-01560-7"}],"container-title":["Acta medica Lituanica"],"original-title":[],"link":[{"URL":"https:\/\/www.journals.vu.lt\/AML\/article\/download\/36707\/38522","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.zurnalai.vu.lt\/AML\/article\/download\/36707\/38523","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journals.vu.lt\/AML\/article\/download\/36707\/38523","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journals.vu.lt\/AML\/article\/download\/36707\/38522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:04:56Z","timestamp":1753704296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journals.vu.lt\/AML\/article\/view\/36707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.15388\/amed.2025.32.1.15","relation":{},"ISSN":["2029-4174","1392-0138"],"issn-type":[{"value":"2029-4174","type":"electronic"},{"value":"1392-0138","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,16]]}}}